BridgeBio's founder saw biotech VCs exclusively funding high-risk "home run" platforms. He built a company to acquire therapies for smaller rare genetic diseases—"singles and doubles"—that were ignored. Aggregating these de-risks the portfolio and creates a major market opportunity.

Yosemite provides unrestricted grants to academic scientists, de-risking novel research and building relationships. This early support creates a unique deal flow engine, leading to investment opportunities in companies that later spin out from this foundational work.

The fund backs underfunded, high-risk ideas that others pass on. The goal isn't just to find a unicorn; it's to contribute to science by definitively disproving a hypothesis. A failure is viewed as "crossing out a wrong answer" for the entire field.

Despite representing only 12% of total Asian out-licensing deals, Korean biotechs account for a disproportionately high 20% of "first-in-class" partnerships. This indicates a strong appetite for novel science and high-risk, high-reward innovation, challenging the stereotype of Asian biotech as purely "fast followers."

To maintain a competitive edge, BridgeBio only pursues programs that are either "first in class" (a novel treatment where none exists) or "best in class" (a demonstrably superior option, like an oral pill versus a daily injection). This strict strategic filter is the core of their entire R&D pipeline selection process.

A successful early-stage strategy involves actively maximizing specific risks—product, market, and timing—to pursue transformative ideas. Conversely, risks related to capital efficiency and team quality should be minimized. This framework pushes a firm to take big, non-obvious swings instead of settling for safer, incremental bets.

Unlike traditional biotech VCs, Yosemite allocates a quarter of its fund to digital health. This reflects its mission to reduce cancer mortality across the entire patient journey, funding solutions for pricing transparency, financial toxicity, and post-approval care.

Yosemite's oncology focus stems from Reed Jobs' experience with his father Steve Jobs' pancreatic cancer. However, the firm deliberately adopts a broad, pan-cancer investment strategy, recognizing the interconnectedness of cancer biology across different tissue types.

Despite big pharma's focus on scalable RNA technologies, Series A funding shows a surprising resurgence in investment for cell and gene therapy. This suggests early-stage VCs see significant unsolved value in areas like targeted delivery and gene editing, bucking the broader clinical and commercial narrative.